Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date March 17, 2022 · Filed April 29, 2022
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,473 |
Reported balance
After 2022-03-17 transaction · row 1
1 source rowRow 1 · 2022-03-17 · Other · Disposed 15,000 · Balance 163,473 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2022-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-17 · Other · Disposed 5,000 · Balance 0 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.31 | $347.55 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 22 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,259 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 29, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.42 | $359.10 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,154 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 28, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.42 | $359.10 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,049 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 27, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.39 | $355.95 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,944 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 26, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.39 | $355.95 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,839 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 23, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.35 | $351.75 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,734 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 22, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.36 | $352.80 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,629 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 21, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.26 | $342.30 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,524 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 20, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.24 | $340.20 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,419 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 19, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.23 | $339.15 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,314 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 16, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.28 | $344.40 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,209 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 15, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.27 | $343.35 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,104 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 14, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.33 | $349.65 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,999 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 13, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.48 | $365.40 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,894 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 12, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.33 | $349.65 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,789 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 09, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.13 | $328.65 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,684 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 08, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.18 | $333.90 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,579 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 07, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.19 | $334.95 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,474 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 06, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.14 | $329.70 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,369 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 02, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,264 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| July 01, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.91 | $305.55 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,159 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 30, 2021 Filed Aug 13, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.93 | $307.65 |
DisclosureSEC source: 0001209191-21-051433 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,054 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 29, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.03 | $318.15 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 30 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,949 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 28, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.16 | $331.80 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 29 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,844 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 25, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.09 | $324.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 28 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,739 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 24, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.09 | $324.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 27 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,634 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 23, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.07 | $322.35 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 26 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,529 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 22, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.05 | $320.25 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 25 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,424 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 21, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.14 | $329.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 24 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,319 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 18, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.99 | $313.95 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 23 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,214 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 17, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.08 | $323.40 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 22 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,109 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 16, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.09 | $324.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,004 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 15, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.09 | $324.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,899 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 14, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.11 | $326.55 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,794 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 11, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.18 | $333.90 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,689 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 10, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.25 | $341.25 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,584 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 09, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.14 | $329.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,479 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 08, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.99 | $313.95 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,374 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 07, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,269 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 04, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.93 | $307.65 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,164 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 03, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.81 | $295.05 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,059 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 02, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.89 | $303.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,954 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 01, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,849 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 28, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.93 | $307.65 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,744 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 27, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,639 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 26, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.85 | $299.25 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,534 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 25, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.89 | $303.45 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,429 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 24, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.02 | $317.10 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,324 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 21, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.06 | $321.30 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,219 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 20, 2021 Filed Jul 9, 2021 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-046210 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,114 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.